According to the new market research report ”Transplant Diagnostics Market by Technology (PCR, NGS, Sanger Sequencing), Product (Instrument, Reagent, Software), Application (HLA, Blood Profile, Pathogen Detection), Type (Heart, Kidney, Liver, Bone Marrow), End User (Hospital) – Global Forecast to 2025“, published by MarketsandMarkets™, transplant diagnostics market is expected to reach USD 5.5 billion by 2025 from USD 3.6 billion in 2019, at a CAGR of 7.2%.

Major Growth Drivers:

The demand for transplant diagnostic products is expected to grow mainly due to factors such as the increasing public-private funding for target research activities, the growing burden of infectious diseases, the increasing number of transplant procedures, and technological advancements in the field of transplant diagnostics.

Expected Revenue Growth:

[227 Pages Report] The transplant diagnostics market is expected to reach USD 5.5 billion by 2025 from USD 3.6 billion in 2019, at a CAGR of 7.2%.

An analysis of the market developments between 2016 and 2019 revealed that product launches & enhancements, partnerships, agreements, and acquisitions were adopted by market players to strengthen their product portfolios and maintain a competitive position in the market. Product launches were the most widely adopted growth strategies.

Download PDF Brochure:   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=2531061  

The molecular assay technologies segment accounted for the largest share of the transplant diagnostics market, by technology, in 2019

The market, by technology, is segmented into molecular and non-molecular assay technologies. In 2019, the molecular assay technologies segment accounted for the largest share of the market. The large share of this segment can be attributed to the benefits offered by molecular assays such as low turnaround time, high procedural efficacy, the study of multiple samples, and real-time sample analysis.

North America accounted for the largest share of the market in 2019

North America is a well-established market for medical devices. The presence of a highly developed healthcare system, high adoption of innovative transplant diagnostic technologies among medical professionals, the large volume of organ transplantation procedures performed in the region, and technological advancements in the field of transplant diagnostics are the major factors driving the market in North America.

Request for sample pages :   https://www.marketsandmarkets.com/requestsampleNew.asp?id=2531061  

Key Market Players

Some of the players in the transplant diagnostics market are Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), bioMérieux SA (France), Immucor, Inc. (US), Becton, Dickinson and Company (US), Merck KGaA (Germany), and Hologic, Inc. (US).

The study involved four major activities in estimating the current size of the HLA typing for the transplants market. Exhaustive secondary research was conducted to collect information on the market and its different subsegments.

According to the new market research report “ HLA Typing for Transplant Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, Reagent, Software), Application (Chimerism, Antibody Screening), End User (Hospital, Diagnolab, Academia) – Global Forecast to 2025“, published by MarketsandMarkets™, HLA typing for the transplants market is expected to reach USD 968 million by 2025 from USD 656 million in 2019, at a CAGR of 6.7%.

Key Factors Driving Market Growth:

The demand for transplant diagnostic products is expected to grow mainly due to factors such as the increasing public-private funding for target research activities, the growing burden of infectious diseases, the growing number of transplant procedures, and technological advancements in the field of transplant diagnostics.

Revenue Growth Analysis:

The HLA typing for the transplants market is expected to reach USD 968 million by 2025 from USD 656 million in 2019, at a CAGR of 6.7%

Download PDF Brochure:   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=96374742

Don’t miss out on business opportunities in HLA typing for transplants market

The HLA typing for transplants market comprises several stakeholders such as original equipment manufacturers (OEMs), product distributors and channel partners, hospitals and transplant centers, emergency care units and trauma centers, diagnostic laboratories, contract manufacturers and third-party suppliers, research laboratories and academic institutes, clinical research organizations (CROS), government and non-governmental regulatory authorities, and market research and consulting firms. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

Browse in-depth TOC on “HLA Typing for Transplant Market”

141 – Tables36 – Figures193 – Pages

The HLA typing for the transplants market, by technology, is segmented into molecular and non-molecular assay technologies. In 2019, the molecular assay technologies segment accounted for the largest share of the HLA typing for the transplants market. The large share of this segment can be attributed to the benefits offered by molecular assays such as low turnaround time, high procedural efficacy, the study of multiple samples, and real-time sample analysis.

Request Sample Report:  https://www.marketsandmarkets.com/requestsampleNew.asp?id=96374742

According to the new market research report ”Transplant Diagnostics Market by Technology (PCR, NGS, Sanger Sequencing), Product (Instrument, Reagent, Software), Application (HLA, Blood Profile, Pathogen Detection), Type (Heart, Kidney, Liver, Bone Marrow), End User (Hospital) – Global Forecast to 2025“, published by MarketsandMarkets™, transplant diagnostics market is expected to reach USD 5.5 billion by 2025 from USD 3.6 billion in 2019, at a CAGR of 7.2%.

Major Growth Drivers:

The demand for transplant diagnostic products is expected to grow mainly due to factors such as the increasing public-private funding for target research activities, the growing burden of infectious diseases, the increasing number of transplant procedures, and technological advancements in the field of transplant diagnostics.

Expected Revenue Growth:

[227 Pages Report] The transplant diagnostics market is expected to reach USD 5.5 billion by 2025 from USD 3.6 billion in 2019, at a CAGR of 7.2%.

An analysis of the market developments between 2016 and 2019 revealed that product launches & enhancements, partnerships, agreements, and acquisitions were adopted by market players to strengthen their product portfolios and maintain a competitive position in the market. Product launches were the most widely adopted growth strategies.

Download PDF Brochure:   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=2531061  

The molecular assay technologies segment accounted for the largest share of the transplant diagnostics market, by technology, in 2019

The market, by technology, is segmented into molecular and non-molecular assay technologies. In 2019, the molecular assay technologies segment accounted for the largest share of the market. The large share of this segment can be attributed to the benefits offered by molecular assays such as low turnaround time, high procedural efficacy, the study of multiple samples, and real-time sample analysis.

North America accounted for the largest share of the market in 2019

North America is a well-established market for medical devices. The presence of a highly developed healthcare system, high adoption of innovative transplant diagnostic technologies among medical professionals, the large volume of organ transplantation procedures performed in the region, and technological advancements in the field of transplant diagnostics are the major factors driving the market in North America.

Request for sample pages :   https://www.marketsandmarkets.com/requestsampleNew.asp?id=2531061  

Key Market Players

Some of the players in the transplant diagnostics market are Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), bioMérieux SA (France), Immucor, Inc. (US), Becton, Dickinson and Company (US), Merck KGaA (Germany), and Hologic, Inc. (US).